---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-076304"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2025-05-22T23:59:59+00:00"
generated_at: "2026-05-20T18:24:19.480613+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Dianthus director Moulder resigns; Read appointed as Class III director

## Summary
- Leon O. Moulder, Jr. resigned from Board effective May 22, 2025, with no disagreement.
- Board appointed Simon Read, Ph.D. as Class III director and to S&T and N&CG Committees.
- Dr. Read receives initial option for 25,000 shares vesting over 3 years; cash compensation of $40k/yr plus $5k per committee.
- Annual meeting elected Garcia and Soteropoulos as Class I directors; advisory vote approved exec compensation; Deloitte ratified as auditor.

## SEC filing metadata
- accession: 0000950170-25-076304
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2025-05-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000095017025076304/0000950170-25-076304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000095017025076304/dnth-20250522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-076304
- JSON: https://secwatch.observer/filing/0000950170-25-076304.json
- Plain text: https://secwatch.observer/filing/0000950170-25-076304.txt

## Key facts
- Executive change
  Simon Read was appointed as Class III director at Dianthus Therapeutics, Inc. /DE/.
  - Action: appointed
  - Role: Class III director
  source text: On May 22, 2025, the Board appointed Simon Read, Ph.D., as a Class III director of the Company and as a member of both the Science and Technology Committee of the Board (the “S&T” Committee) and the Nominating and Corporate Governance Committee of the Board (the “N&CG” Committee), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000095017025076304/0000950170-25-076304-index.htm
- Executive change
  Leon O. Moulder, Jr. resigned as Director at Dianthus Therapeutics, Inc. /DE/.
  - Action: resigned
  - Role: Director
  source text: On May 22 2025, Leon O. Moulder, Jr., a member of the Board of Directors (the “Board”) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000095017025076304/0000950170-25-076304-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.